Download PDF
Thromb Haemost 1977; 38(04): 0801-0808
DOI: 10.1055/s-0038-1651899
Original Article
Schattauer GmbH

Studies on the Biochemistry of Urokinase

Eng Bee Ong
1   New York University Medial Center, 550 First Avenue, New York, N.Y. and the Tulane University Medical Center, 1430 Tulane Avenue, New Orleans, Louisiana 70112, U.S.A.
,
Mercedes E. Soberano
1   New York University Medial Center, 550 First Avenue, New York, N.Y. and the Tulane University Medical Center, 1430 Tulane Avenue, New Orleans, Louisiana 70112, U.S.A.
,
Alan J. Johnson
1   New York University Medial Center, 550 First Avenue, New York, N.Y. and the Tulane University Medical Center, 1430 Tulane Avenue, New Orleans, Louisiana 70112, U.S.A.
,
Guenther Schoellmann
1   New York University Medial Center, 550 First Avenue, New York, N.Y. and the Tulane University Medical Center, 1430 Tulane Avenue, New Orleans, Louisiana 70112, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
04 July 2018 (online)

    Permissions and Reprints

Summary

Direct evidence for an active center histidine residue in urokinase (UK) was obtained with use of newly synthesized peptide chloroketones Ac-Gly-Lys-CH2C1 and Nle-Gly-Lys-CH2C1. Stoichiometric inactivation by DFP provided further evidence that UK is a serine protease. Essential histidine and serine residues were both located in the heavy chain of the 47,0 M. W.UK. The high M.W. form can be converted (catalytically) to the low M. W. form.

9 partially purified human urinary UK preparations (5 with predominantly high M. W. UK), varying in purity and proportion of high and low M. W. forms, were found to be heterogeneous by a number of acrylamide electrophoretic procedures. 7 preparations had strikingly similar molar activities at excess substrate, except for the lower values found in 2 predominantly high M. W. UK preparations from the same supplier. 2 high M. W. UK preparations from another supplier showed a definite increase in activity when assayed at low plasminogen concentration, but this effect was abolished after gel filtration (Sephadex G-25), by further purification with affinity chromatography, or when assayed with excess plasminogen.

The high and low M. W. forms of UK (47,000 and 33,400 M. W.), isolated and purified by Sepharose-EACA-agmatine affinity chromatography were shown to be homogeneous by Coomassie Blue staining after SDS-polyacrylamide gel electrophoresis (PAGE) and by 14C-DFP and 14C-NPGB incorporation before SDS-PAGE. Comparative properties of the high M. W. vs low M. W. forms were as follows: specific activity (104,000 IU/mg vs 226,000) ; 2 chains (33,100 and 18,600 M.W.) linked by disulfide(s) vs a single chain; pi 8.60 (major subform) and pi 8.90 (minor subform) vs pi 8.35, 8.60, 8.70 (major subform) and pi 8.05 (minor subform); and second order kinetics for DFP inactivation (400 vs 770 M−1 min−1). The molar activities were similar (9.6 × 109 and 10.2 × 109IUm/mole) for each form.

 

  • References

  • 1 Ball A. P, Day E. D. 1970; Immunological identification of two urokinases. Thrombosis et Diathesis Haemorrhagica 24: 463.
    PubMedGoogle Scholar
  • 2 Ball A. P, Silver D, Day E. D. 1971; Plasminogen-fibrinogen complex formation as a prelude to fibrinogenolysis. Thrombosis et Diathesis Haemorrhagica 24: 114.
    PubMedGoogle Scholar
  • 3 Barlow G, Lazer L, Reuter A, Tribby T. 1977. Production of plasminogen activator by tissue culture techniques. In: Thrombosis and Urokinase. Paoletti R, Sherry S. (eds.) Academic Press; New York.:
    Google Scholar
  • 4 Burges R. A, Brammer K. W, Coombes J. D. 1965; Molecular weight of urokinase. Nature 208: 894.
    PubMedGoogle Scholar
  • 5 Doleschel W, Auerswald W. 1967; Determination of molecular weight uroprotein fractions with urokinase activity by means of molecular sieving. Med. Pharmacol. Exper 16: 225.
    PubMedGoogle Scholar
  • 6 Fahrney D. E, Gold A. M. 1963; Sulfonylfluorides as inhibitors of esterases. Journal of the American Chemical Society 85: 997.
    CrossrefPubMedGoogle Scholar
  • 7 Geratz J. D. 1970; Inhibition of the thrombin, plasmin and plasminogen activators by amidino compounds. Thrombosis et Diathesis Haemorrhagica 23: 486.
    PubMedGoogle Scholar
  • 8 Geratz J. D. 1971; Inhibition of coagulation and fibrinolysis by aromatic amidine compounds. Thrombosis et Diathesis Haemorrhagica 25: 391.
    PubMedGoogle Scholar
  • 9 Groskopf W. R, Hsieh B, Summaria L, Robbins K. C. 1969; Studies on the active center of human plasmin. Journal of Biological Chemistry 224: 359.
    PubMedGoogle Scholar
  • 10 Holmberg L, Bladh B, Astedt B. 1976; Purification of urokinase by affinity chromatography. Biochimica et biophysica acta 445: 215.
    CrossrefPubMedGoogle Scholar
  • 11 Johnson A. J, McCarty W. R. 1959; The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. Journal of Clinical Investigation 38: 1627.
    CrossrefPubMedGoogle Scholar
  • 12 Kakkar V. V, Sagar S, Lewis M. 1975; Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion. Lancet II: 674.
    PubMedGoogle Scholar
  • 13 Kok P, Astrup T. 1969; Isolation and purification of tissue plasminogen activator and its comparison with urokinase. Biochemistry 8: 79.
    CrossrefPubMedGoogle Scholar
  • 14 Landmann H. 1973; Studies on the mechanism of action of synthetic antifibrinolytics. Thrombosis et Diathesis Haemorrhagica 29: 253.
    PubMedGoogle Scholar
  • 15 Landmann H, Markwardt F. 1970; Irreversible synthetische Inhibitoren der Urokinase. Experientia 26: 145.
    CrossrefPubMedGoogle Scholar
  • 16 Lesuk A, Terminiello L, Traver J. H. 1965; Crystalline human urokinase: some properties. Science 147: 880.
    CrossrefPubMedGoogle Scholar
  • 17 Magnusson S, Hartley B. S. 1972. In: Atlas of Protein Sequence and Structure. Dayhoff M. O. (ed.). Vol. 5, D-109 The National Biomedical Research Foundation; Silver Spring, Md.:
    Google Scholar
  • 18 Ong E. B, Johnson A. J. 1976; a Protamine, a substrate for thrombolytic agents and enzymes of similar specificity. Analytical Biochemistry 75: 568.
    CrossrefPubMedGoogle Scholar
  • 19 Ong E. B, Johnson A. J, Schoellmann G. 1976; b Identification of an active site histidine in urokinase. Biochimica et biophysica acta 429: 252.
    CrossrefPubMedGoogle Scholar
  • 20 Ong E. B, Soberano M. E, Johnson A. J. 1977; Influence of substrate on urokinase assay results, (abstract). Federation Proceedings 36: 288.
    PubMedGoogle Scholar
  • 21 Petkov D, Christova E, Pojarlief I, Stambolieva N. 1975; Structure activity relationships in the urokinase hydrolysis of N-acetyl-L-lysine anilides. Eur. J. Biochem 51: 25.
    CrossrefPubMedGoogle Scholar
  • 22 Robbins K. C, Summaria L, Hsieh B, Shah R. J. 1967; The peptide chains of human plasmin; mechanism of activation of human plasminogen to plasmin. Journal of Biological Chemistry 242: 2333.
    PubMedGoogle Scholar
  • 23 Sharp A. A. 1975. Mechanism of fibrinolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. (eds.) Davidson J. F, Samana M. M, Desnoyers P. C. New York, New York: Raven Press; Vol. 1. 19.
    Google Scholar
  • 24 Sherry S, Alkjaersig N, Fletcher A. P. 1964; Assay of urokinase preparation with the synthetic substrate acetyl-L-lysine methyl ester. Journal of Laboratory and Clinical Medicine 64: 145.
    PubMedGoogle Scholar
  • 25 Sherry S, Fletcher A. P, Alkjaersig N. 1959; Fibrinolysis and fibrinolytic activity in man. Physiological Reviews 39: 343.
    CrossrefPubMedGoogle Scholar
  • 26 Soberano M.E, Ong E. B, Johnson A. J. 1976; a The effects of inhibitors on the catalytic conversion of urokinase. Thrombosis Research 9: 675.
    CrossrefPubMedGoogle Scholar
  • 27 Soberano M. E, Ong E. B, Johnson A. J, Levy M, Schoellmann G. 1976; b Purification and characterization of two forms of urokinase. Biochimica et biophysica acta 445: 763.
    CrossrefPubMedGoogle Scholar
  • 28 Soberano M. E, Ong E. B, Johnson A. J, Schoellmann G, Levy M. 1975; Inhibition studies of urokinase with diisopropylphosphorofluoridate (DFP) and p-nitrophenyl-p’guanidinobenzoate (NPGB) (abstract). Federation Proceedings 36: 288.
    PubMedGoogle Scholar
  • 29 Thorsen S. 1975; Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation; influence of ω-amino-carboxylic acids. Biochimica et biophysica acta 393: 55.
    CrossrefPubMedGoogle Scholar
  • 30 Thorsen S, Glas-Greenwalt P, Astrup T. 1972; Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thrombosis et Diathesis Haemorrhagica 28: 65.
    PubMedGoogle Scholar
  • 31 Walasek O. F. 1975; Isolation and studies of the multimolecular forms of urinary urokinase, (abstract). Federation Proceedings 34: 677.
    PubMedGoogle Scholar
  • 32 Wallen P, Wiman B. 1975 Purification of tissue activator using affinity adsorption on fibrin and hydrophobic interaction chromatography; effect of fibrin on the enzymatic properties of the activator. Proc. Vth. Inti. Congr. Thromb. Haemos.. 348.
    PubMedGoogle Scholar
  • 33 Walton P. L. 1967; The hydrolysis of a-N-acetylglycyl-L-lysine methyl ester by urokinase. Biochimica et biophysica acta 132: 104.
    CrossrefPubMedGoogle Scholar
  • 34 White W. F, Barlow G. H, Mozen M. 1966; The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5: 2160.
    CrossrefPubMedGoogle Scholar
  • 35 Wiman B, Wallen P. 1977; The specific interaction between plasminogen and fibrin; a physiological role of the lysine binding site in plasminogen. Thrombosis Research 1: 213.
    PubMedGoogle Scholar